Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 447,136
  • Shares Outstanding, K 48,549
  • Annual Sales, $ 15,840 K
  • Annual Income, $ -308,480 K
  • 60-Month Beta 0.97
  • Price/Sales 27.92
  • Price/Cash Flow N/A
  • Price/Book 2.84
Trade QURE with:

Options Overview Details

View History
  • Implied Volatility 39.91% ( -57.41%)
  • Historical Volatility 210.94%
  • IV Percentile 2%
  • IV Rank 14.84%
  • IV High 204.23% on 11/13/23
  • IV Low 11.27% on 05/07/24
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4
  • Volume Avg (30-Day) 5,820
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 64,245
  • Open Int (30-Day) 43,512

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.24
  • Number of Estimates 5
  • High Estimate -1.12
  • Low Estimate -1.36
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.73 +165.82%
on 07/05/24
11.35 -12.64%
on 07/10/24
+5.22 (+111.41%)
since 06/17/24
3-Month
3.73 +165.82%
on 07/05/24
11.35 -12.64%
on 07/10/24
+5.24 (+112.31%)
since 04/17/24
52-Week
3.73 +165.82%
on 07/05/24
11.35 -12.64%
on 07/10/24
-0.73 (-6.90%)
since 07/17/23

Most Recent Stories

More News
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 9.66 (+4.89%)
UniQure: Q3 Earnings Snapshot

UniQure: Q3 Earnings Snapshot

QURE : 9.66 (+4.89%)
Why Shares of uniQure Are Up Thursday

The company announced a reorganization that included layoffs.

QURE : 9.66 (+4.89%)
Why Shares of uniQure Are Dropping Tuesday

The company is facing being delisted from the S&P 600 Index.

QURE : 9.66 (+4.89%)
UniQure: Q2 Earnings Snapshot

UniQure: Q2 Earnings Snapshot

QURE : 9.66 (+4.89%)
Why uniQure Stock Cratered This Week

An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors.

QURE : 9.66 (+4.89%)
Why uniQure Stock Is Crashing Today

Investors are focusing on the negative parts of the biotech company's interim results.

QURE : 9.66 (+4.89%)
Stocks Rise on Optimism About the Debt Ceiling

The S&P 500 Index ( $SPX ) ( SPY ) is up +0.09%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is up +0.01%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is up +0.35%. U.S. stock index futures this morning...

ESU24 : 5,669.25 (-0.84%)
NQU24 : 20,227.00 (-1.80%)
SRPT : 148.73 (-0.17%)
MARA : 26.00 (-2.69%)
RIOT : 12.51 (-1.50%)
COIN : 249.20 (-0.91%)
MSTR : 1,647.32 (-1.02%)
SHAK : 89.35 (+1.57%)
QURE : 9.66 (+4.89%)
META : 472.57 (-3.52%)
MNDY : 231.29 (-2.48%)
ALB : 97.65 (-0.06%)
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 9.66 (+4.89%)
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA)...

QURE : 9.66 (+4.89%)
CSL : 438.65 (-0.32%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 10.10
2nd Resistance Point 9.77
1st Resistance Point 9.49
Last Price 9.66
1st Support Level 8.88
2nd Support Level 8.55
3rd Support Level 8.27

See More

52-Week High 11.35
Last Price 9.66
Fibonacci 61.8% 8.44
Fibonacci 50% 7.54
Fibonacci 38.2% 6.64
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar